These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32346557)

  • 41. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
    Rakowski JA; Ahmad S; Holloway RW
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
    Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
    Rubio Pérez MJ
    Case Rep Oncol; 2017; 10(2):433-437. PubMed ID: 28626402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
    Sehouli J; Oskay-Ozcelik G; Kühne J; Stengel D; Hindenburg HJ; Klare P; Heinrich G; Schmalfeldt B; Mertens H; Camara O; Lichtenegger W;
    Ann Oncol; 2006 Jun; 17(6):957-61. PubMed ID: 16600975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.
    Simpkins F; Flores A; Chu C; Berek JS; Lucci J; Murray S; Bauman J; Struemper H; Germaschewski F; Jonak Z; Gardner O; Toso J; Coukos G
    Cancer Immunol Res; 2013 Sep; 1(3):168-78. PubMed ID: 24777679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
    Katsaros D; Oletti MV; Rigault de la Longrais IA; Ferrero A; Celano A; Fracchioli S; Donadio M; Passera R; Cattel L; Bumma C
    Ann Oncol; 2005 Feb; 16(2):300-6. PubMed ID: 15668288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
    Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
    Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
    Ferrandina G; Amadio G; Paris I; Distefano M; Palluzzi E; de Vincenzo R; Ricci C; Scambia G
    Int J Gynecol Cancer; 2017 Jul; 27(6):1141-1148. PubMed ID: 28574933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
    Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
    BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
    Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E;
    Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
    Lebedinsky C; Gómez J; Park YC; Nieto A; Soto-Matos A; Parekh T; Alfaro V; Roy E; Lardelli P; Kahatt C
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1223-31. PubMed ID: 21416137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.